PMI — Stock Film
STOCK FILMSCENE 1/11PMI · $3.03
Stock Expert AI presents
PMI
Picard Medical, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Picard Medical, Inc. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 75 employees. Now — the numbers.

on the stock market since 2025
75 employees
$137.1M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $6.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
73%Products
Products 73%Rentals 27%
73% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $7.0M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
13
very weak

Clearly below the class average.

FINANCIAL STRENGTH
55
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
25
very weak

Clearly below the class average.

GROWTH
41
weak

Clearly below the class average.

PRICE MOMENTUM
8
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Each sale is made at a loss3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $4.9M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 18 buys and 8 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $27M against $4.9M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, PMI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PMI is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film